Neurol. praxi. 2026;27(3):222-226 | DOI: 10.36290/neu.2026.035

Chronic pain and its treatment options

MUDr. Šimon Kozák
Centrum pro léčení a výzkum bolestivých stavů při Klinice rehabilitace a tělovýchovného lékařství 2. LF UK a Fakultní nemocnice Motol a Homolka v Praze

Chronic pain is a major healthcare problem with significant impact on quality of life and healthcare resources. It is defined as pain persisting for more than three months and may arise from multiple pathophysiological mechanisms. Musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis represent common causes. Management of chronic pain requires a comprehensive approach combining pharmacological and non-pharmacological strategies. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain an important option for symptomatic treatment of inflammatory pain. Aceclofenac, available for example as Biofenac 100 mg film-coated tablets, is indicated for the symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. This article reviews the pathophysiology of chronic pain and summarizes current therapeutic approaches.

Keywords: chronic pain, NSAIDs, aceclofenac, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis.

Received: March 10, 2026; Revised: June 30, 2026; Accepted: June 30, 2026; Published: July 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kozák Š. Chronic pain and its treatment options. Neurol. praxi. 2026;27(3):222-226. doi: 10.36290/neu.2026.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 20.7.2027

    References

    1. Akimoto H, Yamazaki R, Hashimoto S, et al. 4'-Hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol. 2000;401(3):429-436. doi:10.1016/S0014-2999(00)00472-6. Go to original source... Go to PubMed...
    2. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. doi:10.1016/j.joca.2019.06.011. Go to original source... Go to PubMed...
    3. Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-284. doi:10.1016/j.cell.2009.09.028. Go to original source... Go to PubMed...
    4. Biofenac 100 mg potahované tablety. Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv. Aktualizovaná verze SPC. Accessed June 24, 2026.
    5. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-1390. doi:10.1016/S0140-6736(07)60635-7. Go to original source... Go to PubMed...
    6. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333. doi:10.1016/j.ejpain.2005.06.009. Go to original source... Go to PubMed...
    7. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18). doi:10.1503/cmaj.170363. Go to original source...
    8. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. doi:10.1038/nrdp.2017.2. Go to original source... Go to PubMed...
    9. Conaghan PG. Osteoarthritis in 2023: current concepts and future directions. Lancet Rheumatol. 2023;5(1). doi:10.1016/S2665-9913(22)00367-5. Go to original source...
    10. da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090). doi:10.1016/S0140-6736(17)31744-0. Go to original source...
    11. Dingle JT, Parker M. NSAID stimulation of human cartilage matrix synthesis. Clin Drug Investig. 1997;14(5):353-362. doi:10.2165/00044011-199714050-00003. Go to original source...
    12. Dooley M, Spencer CM. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-1378. doi:10.2165/00003495-200161090-00012. Go to original source... Go to PubMed...
    13. Eccleston C, Fisher E, Craig L, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2020;8(8). doi:10.1002/14651858.CD003968.pub5. Go to original source... Go to PubMed...
    14. Efstathiou M, Settas L. The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis. Mediterr J Rheumatol. 2017;28(3):133-141. doi:10.31138/mjr.28.3.133. Go to original source... Go to PubMed...
    15. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-2110. doi:10.1016/S0140-6736(21)00392-5. Go to original source... Go to PubMed...
    16. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. doi:10.1002/art.41752. Go to original source...
    17. Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;4(4). doi:10.1002/14651858.CD011279.pub3. Go to original source... Go to PubMed...
    18. Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770. doi:10.1186/1471-2458-11-770. Go to original source... Go to PubMed...
    19. Häuser W, Perrot S, Sommer C, et al. European clinical practice recommendations on chronic primary pain. Eur J Pain. 2021;25(5):906-919. doi:10.1002/ejp.1736. Go to original source... Go to PubMed...
    20. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759. doi:10.1016/S0140-6736(19)30417-9. Go to original source...
    21. Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2022: epidemiology and therapy. Osteoarthritis Cartilage. 2022;30(2):196-206. doi:10.1016/j.joca.2021.11.004. Go to original source... Go to PubMed...
    22. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149-162. doi:10.1002/acr.24131. Go to original source... Go to PubMed...
    23. Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613-624. doi:10.1016/S0140-6736(16)32404-7. Go to original source... Go to PubMed...
    24. Machado GC, Maher CG, Ferreira PH, et al. Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2017;2(2). doi:10.1002/14651858.CD012087. Go to original source... Go to PubMed...
    25. McWilliams DF, Walsh DA. Factors predicting pain progression in osteoarthritis. Ann Rheum Dis. 2017;76(1):36-42. doi:10.1136/annrheumdis-2016-209891. Go to original source...
    26. Nicholas M, Vlaeyen JWS, Rief W, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28-37. doi:10.1097/j.pain.0000000000001390. Go to original source...
    27. Pareek A, Chandurkar N. Efficacy and safety of aceclofenac in the management of pain: a review. Expert Opin Pharmacother. 2013;14(2):247-258. doi:10.1517/14656566.2013.763919. Go to original source...
    28. Singh JA, Guyatt G, Ogdie A, et al. 2022 American College of Rheumatology guideline update for the management of rheumatic diseases. Arthritis Rheumatol. 2022;74(9):1483-1497. doi:10.1002/art.42110. Go to original source... Go to PubMed...
    29. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8. Go to original source...
    30. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015;156(6):1003-1007. doi:10.1097/j.pain.0000000000000160. Go to original source... Go to PubMed...
    31. van der Heijde D, Ramiro S, Landewé R, et al. 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82(1):19-34. doi:10.1136/ard-2022-223296. Go to original source...
    32. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A):2S-8S. doi:10.1016/S0002-9343(97)00203-9. Go to original source... Go to PubMed...
    33. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl). doi:10.1016/j.pain.2010.09.030. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.